SATRALIZUMAB
( DrugBank: Satralizumab / KEGG DRUG: Satralizumab )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 11 | Myasthenia gravis | 9 |
| 13 | Multiple sclerosis | 28 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 86 | Pulmonary arterial hypertension | 2 |
11. Myasthenia gravis
Clinical trials : 439 / Drugs : 223 - (DrugBank : 73) / Drug target genes : 50 - Drug target pathways : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
13. Multiple sclerosis
Clinical trials : 3,685 / Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
86. Pulmonary arterial hypertension
Clinical trials : 1,288 / Drugs : 565 - (DrugBank : 126) / Drug target genes : 81 - Drug target pathways : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|